Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will publish impact assessments, modelling and further detail on the UK-US pharmaceutical trade deal.

Tens of thousands of National Health Service patients will benefit from this deal, which will secure and expand access to vital drugs, and thereby safeguard our medicines supply chain.

Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.

This deal is a vital investment that builds on the strength of our NHS and world leading life sciences without taking essential funding from our frontline NHS services.

There are no current plans to publish an impact assessment or modelling on the United Kingdom and United States’ pharmaceutical trade deal. Further detail on the deal will be shared in due course.